Eliglustat combined with CD30-targeted therapy for CD30+ lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, open-label Phase 1/2 trial combining the glucosylceramide synthase inhibitor eliglustat with CD30-targeted immunotherapies to try to improve responses in CD30-positive lymphoma. The rationale is that inhibiting GSL synthesis may alter N-glycan structures on CD30 and enhance immune synapse formation and anti-tumor activity. Participants are adults with confirmed CD30+ lymphoma, measurable disease, and prior antitumor therapy; key endpoints include safety, complete response rate for the CAR‑T plus eliglustat arm, and progression-free survival for the brentuximab vedotin plus eliglustat arm. The trial is conducted at the People's Liberation Army General Hospital in Beijing with planned Phase I safety evaluation followed by Phase II efficacy expansion.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 to 75 years of age.
* ECOG performance of less than 2.
* Subjects must have histological confirmation CD30+ lymphoma.
* Patients must have at least one line of antitumor therapy
* Life expectancy of at least 3 months.
* Subjects with lymphoma must have at least one measureable lesion \>1cm as defined by lymphoma response criteria.
* Previous treatment must be completed for more than 4 weeks prior to the enrollment of this study, and subjects have recovered to ≤ grade 1 toxicity.
* Subjects with autologous hematopoietic stem-cell transplantation are eligible which must be more than 3 months.
* Subjects must have adequate marrow, live, renal and heart functions.

Exclusion Criteria:

* Participants with CD30- lymphoma.
* CYP2D6 ultra-rapid metabolizers (URMs).
* The patients is taking a CYP2D6 inhibitor and/or concomitantly with a strong or moderate CYP3A inhibitor.
* Subjects with a history of severe hypersensitivity reactions to CD30 target immunotherapy.
* History of allergy or intolerance to study drug components.
* Known brain metastases or active central nervous system (CNS). Subjects with CNS metastases who were treated with radiotherapy for at least 3 months prior to enrollment, have no central nervous symptoms and are off corticosteroids, are eligible for enrollment, but require a brain MRI screening.
* Uncontrolled intercurrent illness, including ongoing or active systemic infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (excluding insignificant sinus bradycardia and sinus tachycardia) or psychiatric illness/social situations and any other illness that would limit compliance with study requirements and jeopardize the safety of the patient.
* Known positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS).
* Previous or concurrent cancer within 3 years prior to treatment start except for curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)\].
* Major surgery or trauma occurred within 28 days prior to enrollment, or major side effects have not been recovered.
* Vaccination within 30 days of study enrollment.
* Active alimentary tract hemorrhage or history of alimentary tract hemorrhage in 1 month.
* Pregnant or breast-feeding. Women of childbearing potential must have a pregnancy test performed within 7 days before the enrollment, and a negative result must be documented
* Being participating any other trials or withdraw within 4 weeks.
* Unable to swallow and retain oral medication, malabsorption syndrome, conditions that significantly impair gastrointestinal function, total gastrectomy or small bowel resection, ulcerative colitis, symptomatic inflammatory bowel disease, partial or complete intestinal obstruction.
* Researchers believe that other reasons are not suitable for clinical trials.

Where it's running

• People's Liberation Army General Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Han wei dong
• Email: hanwdrsw@sina.com
• Phone: +861055499341

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma

  This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.

  Recruiting Phase 1 Leukos Biotech S.L. · Barcelona, Barcelona · NCT07914348

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma

  This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07779018

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• Glofit-GemOx Bridging to Liso-cel for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests whether a bridging therapy with Glofit-GemOx followed by lisocabtagene maraleucel helps people with relapsed or refractory large B-cell lymphoma.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07711483

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.